BBK is looking to bring balance to the doctor, patient relationship by improving lines of communication and the productivity of office visits with its online resource, Clinical Notifier.
InvVax’s universal flu vaccine candidate has demonstrated preclinical success as the company prepares for a Phase I clinical trial, supported by a Series A fundraising round.
Sponsors are encouraged to use a master protocol approach to accelerate clinical development programs, though experts say the advantages and challenges should be carefully weighed.
Clinical trial transparency efforts are falling short, with half of trials left unreported, according to a recent UK parliamentary committee report, which calls on the government to take action.
ScieGen Pharmaceuticals has recalled certain batches of hypertension drug irbesartan, after a probable carcinogen was detected in supplier Aurobindo’s API.
The CRO WuXi AppTec and Schrödinger have launched Faxian Therapeutics, a new company that will focus on accelerating drug discovery and advancing new therapies through global collaboration.
Thermo Fisher opened a new business center and biorepository along with an expanded distribution center, to help support mounting demand for clinical trial supply chain logistics.
A consumer rights watchdog is calling on regulators to suspend research at a Minnesota-based medical facility in response to concerns surrounding informed consent for a study involving Ketamine.
President Donald Trump signed the SUPPORT Act granting the FDA additional authority to combat the opioid epidemic, but a pain management CRO argues that opioid addiction isn't the only crisis.
Nascent next-generation processing technologies are expected to have a significant effect on how drugs are brought to market – faster and more cost-effectively than ever before, says industry expert.
President Donald Trump signed the SUPPORT act granting the FDA additional authority to combat the opioid epidemic, but a pain management CRO argues that opioid addiction isn’t the only crisis.
Aspen will spend a record sum on transforming its Port Elizabeth manufacturing site, marking the ‘single biggest pharmaceutical investment’ in South Africa to date.
AAPS PharmSci 360 is a new conference this year, created in response to a desire for “fresh science,” specifically with chemical and biomolecular components. So what can you expect?
SPI Pharma has launched Mannogem XL mannitol for the production of various forms of tablets, which the firm says enhances productivity compared to compendial mannitol.
A proof-of-concept study using patient-derived cells to test drug response in clinical trials demonstrates the benefits of precision medicine, movement to which is the future of study design, says researcher.
Idifarma’s seventh project with Palobiofarma will see the CDMO provide drug formulation, development and manufacturing services for respiratory disease candidate PBF-2987.
The FDA’s recent guidance on complex generics ‘increases clarity’ for Indian drugmakers targeting the US market, according to India Ratings and Research.
Icon reported a record number of new business awards in Q3 and outlined its three-part patient recruitment strategy as well as global hiring – and acquiring – plans.
Compass Pathways’ psilocybin therapy for treatment-resistant depression has received a breakthrough status to accelerate development – at a time when the incidence of mental illness is rapidly increasing.
WuXi Biologics and CANbridge Pharmaceutical have entered into a long-term partnership to develop and commercialize a portfolio of biotherapeutics for rare diseases.
SGS announced it will provide new in vitro toxicology services at its Mississauga, Canada Laboratory following an investment in instruments and laboratory capabilities.
LabCorp sees significant opportunity to grow its Covance Drug Development business in the face of a potentially challenging 2019 and is on track to deliver costs savings as part of its LaunchPad initiatives.
An MHRA audit of Recipharm’s facility in Ashton-under-Lyne has revealed the CDMO was deficient in certain manufacturing procedures for potent products.
Marken is centralizing its brokerage management services in conjunction with UPS, as the rise in global trials brings more vendors and new challenges into the fold.
The India-based CRO Veeda Clinical Research has completed a second audit by the Malaysia Regulatory Agency, following 18 US FDA inspections over the past two years.
Iqvia reported a record quarter of contracted bookings during its third quarter earnings call, as the company continues to invest in its technology platform while securing new customers, say CEO.
Velesco Pharma has expanded its analytical research and development capabilities to meet a growing demand for its services after acquiring a new facility in Michigan.
CROs don’t have sufficient access to clinical research associates (CRAs) to realize market growth, says the CEO of VIARES, which is working to create a new trained and accredited workforce.
BioIVT will use its new internal cloud-based Quality Management System to manage clinical trial data at all of its locations, following the acquisition of five companies since 2017.
Assay.Works and 2bind are partnering to expand the range of discovery services provided for companies in the pharmaceutical and biotech industry, and academic organizations.
Quotient Sciences, a drug development services organization, will expand its operations with a new early phase formulation development and clinical trial manufacturing facility.
Changes at the state and federal level are paving the way for increased participation in clinical trials by providing patient reimbursement for study-related costs.
Certara is using Hedera’s next-generation distributed ledger technology to help the pharmaceutical industry and other stakeholders to ‘capitalize on the myriad of seemingly insignificant activities.’
CPhI panelists agree that there is going to be significant consolidation in the CDMO space – and express the desire to work with fewer suppliers, the top five of which currently account for 15% of the total market.
A review of ‘disabling and potentially long-lasting side effects’ reported in relation to treatments of fluoroquinolone and quinolone prompted the PRAC recommendation.
